retatrutide triple hormone receptor agonist benefits Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the Efficacy and Safety of GLP‐1

Your biology shifts first

Sleep disruption

At the moment, some medications can collaborate in the treatment of MASLD, some of them approved for the treatment of comorbidities such as GLP-1 agonists indicated for the treatment of T2DM or obesity, but also with benefit in the MASH treatment (9, 10)

Many women report improved mental clarity, reduced food noise, and a healthier relationship with eating when dosing is tailored to their physiology rather than driven by scale goals

Retatrutide isn't currently licensed or available for prescribing in the UK

Plant proteins can impact taste and other sensory properties, introduce off-notes, or change texture